Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 8797586)

1.

Expression of cell cycle-regulated proteins in prostate cancer.

Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A.

Cancer Res. 1996 Sep 15;56(18):4159-63.

2.

A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.

Mu K, Li L, Yang Q, Yun H, Kharaziha P, Ye DW, Auer G, Lagercrantz SB, Zetterberg A.

Ann Diagn Pathol. 2015 May 12. pii: S1092-9134(15)00079-9. doi: 10.1016/j.anndiagpath.2015.05.002. [Epub ahead of print]

PMID:
26049669
3.

Biological significance of perineural invasion (PNI) in prostate cancer.

Fromont G, Godet J, Pires C, Yacoub M, Dore B, Irani J.

Prostate. 2012 Apr;72(5):542-8. doi: 10.1002/pros.21456. Epub 2011 Jul 11.

PMID:
21748758
4.

Leukocyte-mediated cell dissemination and metastasis: findings from multiple types of human tumors.

Man YG, Mason J, Harley R, Kim YH, Zhu K, Gardner WA.

J Cell Biochem. 2011 Apr;112(4):1154-67. doi: 10.1002/jcb.23035.

PMID:
21312236
5.

Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy.

Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, Naito S, Yokomizo A, Kuroiwa K, Tokunaga S, Kato S, Hiura H, Samori T, Kang D, Uchiumi T.

Cancer Sci. 2011 Mar;102(3):639-47. doi: 10.1111/j.1349-7006.2010.01828.x. Epub 2011 Jan 23.

PMID:
21205079
6.

[Proliferation markers used in histological studies].

Kirik OV, Beznin GV, Korzhevskiĭ DE.

Morfologiia. 2009;136(6):95-100. Review. Russian.

PMID:
20358782
7.

[The proliferative properties and regulators of the mitotic cell cycle of prostate adenocarcinoma].

Tarasova MV, Pozharisskiĭ KM, Ten VP, Arzumanov AA, Kudaĭbergenova AG.

Arkh Patol. 2009 Nov-Dec;71(6):20-3. Russian.

PMID:
20131501
8.

The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.

Tsamandas AC, Kardamakis D, Tsiamalos P, Liava A, Tzelepi V, Vassiliou V, Petsas T, Vagenas K, Zolota V, Scopa CD.

Anticancer Res. 2009 Feb;29(2):703-9.

9.

Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.

Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M, Alanen K.

APMIS. 2009 Mar;117(3):151-61. doi: 10.1111/j.1600-0463.2008.00002.x.

PMID:
19245588
11.

Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.

Zellweger T, Günther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rüfenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L.

Int J Cancer. 2009 May 1;124(9):2116-23. doi: 10.1002/ijc.24174.

PMID:
19117060
12.
13.

BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.

Schwartz AM, Man YG, Rezaei MK, Simmens SJ, Berg PE.

Mod Pathol. 2009 Jan;22(1):1-6. doi: 10.1038/modpathol.2008.168. Epub 2008 Oct 17.

14.

Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence.

Parmigiani RB, Bettoni F, Grosso DM, Lopes A, Cunha IW, Soares FA, Carvalho AL, Fonseca F, Camargo AA.

Int J Cancer. 2008 May 15;122(10):2385-90. doi: 10.1002/ijc.23369.

PMID:
18214856
15.

Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.

May M, Siegsmund M, Hammermann F, Loy V, Gunia S.

Scand J Urol Nephrol. 2007;41(5):375-81. Epub 2007 Jul 27.

PMID:
17853019
16.

The expression of metallothioneins on imprint smears of prostate carcinoma: correlation with clinicopathologic parameters and tumor proliferative capacity.

Athanassiadou P, Bantis A, Gonidi M, Athanassiades P, Agelonidou E, Grapsa D, Nikolopoulou P, Patsouris E.

Tumori. 2007 Mar-Apr;93(2):189-94.

18.

Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

Aaltomaa S, Kärjä V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, Mokka R.

Anticancer Res. 2006 Nov-Dec;26(6C):4873-8.

19.

Measuring proliferation in breast cancer: practicalities and applications.

Beresford MJ, Wilson GD, Makris A.

Breast Cancer Res. 2006;8(6):216. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk